Opioid addiction is a serious problem in the United States, with approximately 2.1 million people suffering from an opioid use disorder in 2018.1 Opioid withdrawal symptoms can be debilitating and can include anxiety, nausea, vomiting, diarrhea, muscle aches, and insomnia.2 Until recently, there were limited options for treating opioid withdrawal symptoms, but the approval of Lucemyra (lofexidine hydrochloride) in 2018 has revolutionized the treatment of opioid withdrawal symptoms.
Lucemyra is an oral medication approved by the U.S. Food and Drug Administration (FDA) for the mitigation of opioid withdrawal symptoms.3 It is a selective alpha-2-adrenergic receptor agonist that works by reducing the release of norepinephrine, a neurotransmitter that is involved in the body’s response to stress.4 By blocking the release of norepinephrine, Lucemyra reduces the symptoms of opioid withdrawal.
Lucemyra is typically used in conjunction with other medications and behavioral therapies to treat opioid withdrawal symptoms. It is administered as an oral solution and is typically taken twice a day for up to 14 days.5 The dosage of Lucemyra is based on the patient’s age, weight, and severity of symptoms.6
The most significant benefit of Lucemyra is its ability to reduce the severity of opioid withdrawal symptoms.7 Studies have shown that it can reduce the severity of symptoms such as anxiety, nausea, vomiting, diarrhea, muscle aches, and insomnia.8 It also has fewer side effects than other medications used to treat opioid withdrawal symptoms, such as clonidine.9 In addition to its effectiveness in treating opioid withdrawal symptoms, Lucemyra has also been shown to be effective in helping patients maintain abstinence from opioids.10 Studies have found that patients taking Lucemyra were more likely to remain abstinent from opioids for longer periods of time than those taking a placebo.11 This is an important benefit of Lucemyra, as it can help patients stay in recovery and avoid relapse.
Lucemyra is a revolutionary medication that has had a significant impact on the treatment of opioid withdrawal symptoms. It is effective in reducing the severity of symptoms and has fewer side effects than other medications used to treat opioid withdrawal. In addition, it has been shown to be effective in helping patients maintain abstinence from opioids. For these reasons, Lucemyra is an important tool in treating opioid addiction and helping patients stay in recovery.
1.
PET-CT finds further-reaching metastases in patients with locally advanced breast cancer.
2.
Reasons Behind Refusing Stem Cell Transplantation in Certain Myeloma Patients.
3.
Hospitalization and mortality rates are associated with exposure to the omicron variant of COVID-19 in patients with solid cancer.
4.
AI System Beats Radiologists in Detecting Clinically Significant Prostate Cancer
5.
In heavily pretreated DLBCL, Triplet Scores a Survival Victory.
1.
The Precision Revolution: Bispecific Antibodies and Antibody-Drug Conjugates Reshaping the Oncology Landscape
2.
Is AI The New Radiologist For Breast MRI?
3.
Uncovering New Hope for Follicular Lymphoma Patients
4.
The Silent Signs: Uncovering Stomach Cancer Symptoms Before It's Too Late
5.
Unveiling the Chadwick Sign: A Revolutionary New Tool for Detecting Early Signs of Cancer
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
2.
Efficient Management of First line ALK-rearranged NSCLC - Part V
3.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Current Cancer Scenario in India- Importance of Genomic Testing & Advancement in Diagnosis and Treatment
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation